UNCY News and Press, Unicycive Therapeutics Inc. From 09/16/21

The following slide deck was published by Unicycive Therapeutics, Inc. in conjunction with this event. For further details see: Unicycive Therapeutics (UNCY) Investor Presentation - Slideshow

Unicycive Therapeutics to be Added to Russell Microcap® Index PR Newswire LOS ALTOS, Calif. , Sept. 15, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidne...

Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire LOS ALTOS, Calif. , Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing the...

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results Completed initial public offering in July 2021 with gross proceeds of $25 million Planned meeting with the U.S. FDA in Q4 2021 to align on Renazorb program PR Newswire LOS ALTOS, Calif. , ...

Unicycive Therapeutics Inc. (NASDAQ:UNCY) traded today at a new 52-week low of $2.68. So far today approximately 521,000 shares have been exchanged, as compared to an average 30-day volume of 0,000 shares. Based on a current price of $2.78, Unicycive Therapeutics Inc. is currently 7.3% a...